Minute Insight: Vicarious’ Future Gets Precarious

The surgical robotics start-up may be de-listed from the New York Stock Exchange (NYSE) due to its low current share price. Some analysts believe the company can survive long enough to earn FDA de novo clearance for its robotic surgical system.

Minute Insight
• Source: Citeline/Alamy

The New York Stock Exchange issued Vicarious Surgical a de-listing notice; the robotics company has failed to comply NYSE rules that forbid listed companies from having a share price of less than $1 for 30 consecutive trading days.

Vicarious shares are now trading at less than 70 cents.

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Financing

Investor Eye: Intuitive Surgical Hops, Skips, And Jumps Into VC

 

When a large medtech company sets up a venture fund, it typically invests in technologies that are adjacent to its pre-existing portfolio. Intuitive Surgical’s approach is different.

News We’re Watching: New FDA Approvals For Breast Implant, Colon Cancer Test, Imaging Agent; TAP Expansion, AI Standards

This week, Establishment Labs Holdings announced the FDA gave it premarket approval for Motiva breast implant, Cologuard lands FDA approval for Cologuard Plus and GE HealthCare gets FDA nod for a new imaging agent. The FDA announces another expansion for TAP into ophthalmology and radiology. The AAMI and CTA will join forces to develop standards for AI and ML-enabled health care products.  

MI-Business (Free-2): Prison Is the First Mental Health Visit for Many in Spain

 
• By 

Spain has one of the highest incarceration rates in Europe, with 160 individuals imprisoned per 100,000 residents. In 2020, 43,494 people were incarcerated in facilities not managed by regional health authorities — essentially all regions except Catalonia, the Basque Country, and Navarra.

Q1 Earnings Call Recap: Medtech Giants Brace for Tariffs Impact - Clone

 
• By 

The medtech companies navigate tariffs through a mix of proactive manufacturing moves, financial planning and global supply chain adjustments. Medtech Insight combined comments from executives made during their first-quarter earning calls to get an industry pulse check on how the surge of tariffs im

More from Business

test carousel-Medtech

 
• By 

test carousel-Medtech

test carousel

 
• By 

test carousel-HBW

News We’re Watching: New FDA Approvals For Breast Implant, Colon Cancer Test, Imaging Agent; TAP Expansion, AI Standards

This week, Establishment Labs Holdings announced the FDA gave it premarket approval for Motiva breast implant, Cologuard lands FDA approval for Cologuard Plus and GE HealthCare gets FDA nod for a new imaging agent. The FDA announces another expansion for TAP into ophthalmology and radiology. The AAMI and CTA will join forces to develop standards for AI and ML-enabled health care products.